WO2023104904A3 - The sars-cov-2 and variants use two independent cell receptors to replicate - Google Patents

The sars-cov-2 and variants use two independent cell receptors to replicate Download PDF

Info

Publication number
WO2023104904A3
WO2023104904A3 PCT/EP2022/084833 EP2022084833W WO2023104904A3 WO 2023104904 A3 WO2023104904 A3 WO 2023104904A3 EP 2022084833 W EP2022084833 W EP 2022084833W WO 2023104904 A3 WO2023104904 A3 WO 2023104904A3
Authority
WO
WIPO (PCT)
Prior art keywords
cov
sars
ace2
lsr
replication
Prior art date
Application number
PCT/EP2022/084833
Other languages
French (fr)
Other versions
WO2023104904A2 (en
Inventor
Bernard Bihain
Olivier ROITEL
Benoît THOUVENOT
Original Assignee
Genclis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genclis filed Critical Genclis
Publication of WO2023104904A2 publication Critical patent/WO2023104904A2/en
Publication of WO2023104904A3 publication Critical patent/WO2023104904A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present disclosure relates to a compositions and methods for prevention and/or treatment of COVID-19 disease caused by the SARS-CoV-2. The Angiotensin-Converting Enzyme 2 (ACE2) that delivers viral RNA into the cytoplasm was heretofore the sole known SARS- CoV-2 receptor. Disclosed herein is the identification of another SARS-CoV-2 receptor. Namely, the Lipolysis Stimulated Receptor (LSR). LSR provides an endocytic route as effective for the replication of SARS-CoV-2 as ACE2. LSR and ACE2 contributions to viral replication are coordinated by free fatty acids (FFA). Unsaturated FFA irreversibly suppress SARS-CoV-2 capacity to bind ACE2. At the same time, both saturated and unsaturated FFA activate LSR. Activated LSR endocytoses ACE2 competent and incompetent SARS-CoV-2 yielding immediate or delayed production of ACE2 competent progeny. Disclosed herein are compositions and methods directed toward both ACE2 and LSR mediated routes of viral entry and replication, which reduce the severity and transmission of SARS-CoV-2.
PCT/EP2022/084833 2021-12-08 2022-12-07 The sars-cov-2 and variants use two independent cell receptors to replicate WO2023104904A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2113141 2021-12-08
FRFR2113141 2021-12-08

Publications (2)

Publication Number Publication Date
WO2023104904A2 WO2023104904A2 (en) 2023-06-15
WO2023104904A3 true WO2023104904A3 (en) 2023-07-20

Family

ID=85132800

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2022/084833 WO2023104904A2 (en) 2021-12-08 2022-12-07 The sars-cov-2 and variants use two independent cell receptors to replicate

Country Status (1)

Country Link
WO (1) WO2023104904A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111088283A (en) * 2020-03-20 2020-05-01 苏州奥特铭医药科技有限公司 mVSV viral vector, viral vector vaccine thereof and mVSV-mediated novel coronary pneumonia vaccine
WO2021045836A1 (en) * 2020-04-02 2021-03-11 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
ES2136092T3 (en) 1991-09-23 1999-11-16 Medical Res Council PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES.
ATE244763T1 (en) 1992-02-11 2003-07-15 Cell Genesys Inc ACHIEVEMENT OF HOMOZYGOTE THROUGH TARGETED GENETIC EVENTS
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
DE60144063D1 (en) 2000-12-18 2011-03-31 Dyax Corp DIRECTED LIBRARIES GENETICALLY PACKAGED
EP1887088A1 (en) 2006-07-20 2008-02-13 Transmedi SA Transcription infidelity, detection and uses thereof
EP3753947A1 (en) 2007-09-14 2020-12-23 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
JP6881813B2 (en) 2014-04-23 2021-06-02 モデルナティーエックス， インコーポレイテッド Nucleic acid vaccine
US20200085852A1 (en) 2015-08-05 2020-03-19 Curevac Ag Epidermal mrna vaccine
EP4349404A3 (en) 2015-10-22 2024-06-19 ModernaTX, Inc. Respiratory virus vaccines
EP4148427A1 (en) 2016-03-18 2023-03-15 Genclis Molecular origin of allergy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111088283A (en) * 2020-03-20 2020-05-01 苏州奥特铭医药科技有限公司 mVSV viral vector, viral vector vaccine thereof and mVSV-mediated novel coronary pneumonia vaccine
WO2021045836A1 (en) * 2020-04-02 2021-03-11 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BARBERIS ELETTRA ET AL: "Large-Scale Plasma Analysis Revealed New Mechanisms and Molecules Associated with the Host Response to SARS-CoV-2", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 21, no. 22, 16 November 2020 (2020-11-16), pages 1 - 25, XP055854390, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7696386/pdf/ijms-21-08623.pdf> DOI: 10.3390/ijms21228623 *
CARRIQUE LOIC ET AL: "The SARS-CoV-2 Spike harbours a lipid binding pocket which modulates stability of the prefusion trimer", BIORXIV, 13 August 2020 (2020-08-13), XP093037159, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2020.08.13.249177v1.full.pdf> [retrieved on 20230404], DOI: 10.1101/2020.08.13.249177 *
CREECH BUDDY ET AL: "SARS-CoV-2 Vaccines | Vaccination | JAMA | JAMA Network", JAMA, 26 February 2021 (2021-02-26), XP093039331, Retrieved from the Internet <URL:https://jamanetwork.com/journals/jama/fullarticle/2777059> [retrieved on 20230414], DOI: 10.1001/jama.2021.3199 *
GOC ANNA ET AL: "Abstract", SCIENTIFIC REPORTS, vol. 11, no. 1, 4 March 2021 (2021-03-04), XP055844623, Retrieved from the Internet <URL:https://www.nature.com/articles/s41598-021-84850-1.pdf> DOI: 10.1038/s41598-021-84850-1 *
IDRIS ADI ET AL: "A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-19", MOLECULAR THERAPY, vol. 29, no. 7, 1 July 2021 (2021-07-01), US, pages 2219 - 2226, XP055869239, ISSN: 1525-0016, Retrieved from the Internet <URL:https://ars.els-cdn.com/content/image/1-s2.0-S1525001621002562-mmc4.pdf> DOI: 10.1016/j.ymthe.2021.05.004 *
LADNER JASON T. ET AL: "Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic human coronaviruses", CELL REPORTS MEDICINE, vol. 2, no. 1, 1 January 2021 (2021-01-01), pages 100189, XP055847640, ISSN: 2666-3791, Retrieved from the Internet <URL:https://www.cell.com/cell-reports-medicine/pdfExtended/S2666-3791(20)30244-5> DOI: 10.1016/j.xcrm.2020.100189 *
THEKEN KATHERINE N. ET AL: "The roles of lipids in SARS-CoV-2 viral replication and the host immune response", JOURNAL OF LIPID RESEARCH, vol. 62, 1 January 2021 (2021-01-01), US, pages 100129, XP093037161, ISSN: 0022-2275, DOI: 10.1016/j.jlr.2021.100129 *
TOELZER CHRISTINE ET AL: "Free fatty acid binding pocket in the locked structure of SARS-CoV-2 spike protein", SCIENCE (AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE), 6 November 2020 (2020-11-06), United States, pages 725 - 730, XP055845592, Retrieved from the Internet <URL:https://www.science.org/doi/10.1126/science.abd3255> [retrieved on 20210928], DOI: 10.1126/science.abd3255 *
WANG DONGLIANG ET AL: "Immunoinformatic Analysis of T- and B-Cell Epitopes for SARS-CoV-2 Vaccine Design", VACCINES, vol. 8, no. 3, 3 July 2020 (2020-07-03), XP055865893, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563688/pdf/vaccines-08-00355.pdf> DOI: 10.3390/vaccines8030355 *
ZHANG MIN ET AL: "LSR Promotes Cell Proliferation and Invasion in Lung Cancer", COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE, vol. 2021, 8 March 2021 (2021-03-08), pages 1 - 8, XP093021769, ISSN: 1748-670X, Retrieved from the Internet <URL:https://downloads.hindawi.com/journals/cmmm/2021/6651907.pdf> DOI: 10.1155/2021/6651907 *

Also Published As

Publication number Publication date
WO2023104904A2 (en) 2023-06-15

Similar Documents

Publication Publication Date Title
EA202193242A1 (en) CARTRIDGE FOR AEROSOL GENERATING DEVICE
MX2020010227A (en) Constructs targeting cd22 and uses thereof.
AR083957A1 (en) TREATMENT TO MODULATE NK CELLS AND METHODS TO TREAT HEMATOLOGICAL MALIGNITY
MA32729B1 (en) 1-amino acid derivatives
MY157525A (en) Inhibitors of the renal outer medullary potassium channel
MX2011012181A (en) Composition and method for controlling plant diseases.
MX2022002198A (en) Compositions and methods for modulating splicing and protein expression.
WO2004050620A3 (en) Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex
MX2021014465A (en) Rnai constructs for inhibiting scap expression and methods of use thereof.
WO2019175799A3 (en) Method of modulating tigit and pd-1 signalling pathways using 1,2,4-oxadiazole compounds
MX2021013341A (en) Solid forms of a glyt1 inhibitor.
WO2022036126A3 (en) RNAi CONSTRUCTS AND METHODS FOR INHIBITING MARC1 EXPRESSION
WO2023104904A3 (en) The sars-cov-2 and variants use two independent cell receptors to replicate
MY150817A (en) Crystalline form of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid
ZA202206266B (en) Pd-l1 antagonist compound
GB201312965D0 (en) Stem cell factor inhibitor
MX2022006735A (en) Substituted nucleoside analogs as prmt5 inhibitors.
CL2020002644A1 (en) Composition to modulate genes responsible for the general functions of the skin, comprising the combination of an extract of hymenaea courbaril and a mixture of sodium and sarcosine cocoylamino acids and potassium aspartate and magnesium aspartate (divisional application 03354-2018)
AR110750A1 (en) METHOD FOR IMPROVING PLANT HEALTH AND ROOT DEVELOPMENT
CR8376A (en) METHOD FOR PRODUCING DERIVATIVES OF (3-OXO-2,3-DIHIDRO-1 H-ISOINDOL-1-IL) -ACETILGUANIDINE
CR20230261A (en) Cocrystal of a cdk inhibitor
EA202193054A1 (en) STABLE COMPOSITIONS OF ALBUVIRTIDE
WO2012003477A3 (en) Inhibition of inflammation bysimultaneous blockade of multiple prostanoid receptors
MA33512B1 (en) INHIBITORS OF CATHEPSIN C
MX2022012419A (en) Adhesive composition for a glue stick.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22850641

Country of ref document: EP

Kind code of ref document: A2